


Form PTO-892 U.S. Department of Commerce	Serial Number <b>09/756,411</b>	Group Art Unit <b>1623</b>	Attachment to Paper Number	<b>15</b>
Notice of References Cited	APPLICANT(S) <b>Lori et al.</b>			

**Other References (Including Author, Title, Date, Pertinent Pages, etc.)**

*	S†	<u>Biochemicals/Organic Compounds for Research and Diagnostic Reagents</u> , Sigma Chemical Co. (catalog), St. Louis, MO, 1992, pp. 321, 341-342.
*	T†	Feorino et al., "Prevention of Activation of HIV-1 by Antiviral Agents in OM-10.1 Cells," <i>Antiviral Chemistry &amp; Chemotherapy</i> , 4(1), 55-63 (1993).
*	U†	Snyder et al. (I), "Effects of Hydroxyurea and Thymidine Derivatives on the Uptake and Metabolism of Deoxycytidine and Arabinosylcytosine in Log Phase and Contact-Inhibited Human Fibroblasts," <i>Molecular Pharmacology</i> , 28(6), 574-580 (1985); see p. 578 in particular.
*	V	Licastro et al., "Inhibition of Polymerases- $\alpha$ and - $\beta$ Completely Blocks DNA Repair Induced by UV Irradiation in Cultured Mouse Neuronal Cells," <i>Biochemical Biophysical Res. Comm.</i> , 132(3), 929-933 (November 15, 1985).
*	W†	Busso et al., "Cellular Pharmacology and Anti-HIV Activity of 2',3'-Dideoxyguanosine," <i>AIDS Res. Human Retroviruses</i> , 6(9), 1139-1146 (1990).
*	X	R. S. Root-Bernstein(I), "AIDS IS More Than HIV: Part I," <i>Genetic Engineering News</i> , September 1, 1992, pp. 4-6.
*	Y	R. S. Root-Bernstein(II), "AIDS IS More Than HIV: Part II," <i>Genetic Engineering News</i> , September 15, 1992, pp. 4-5.
*	Z	"Kaposi's Sarcoma and <i>Pneumocystis</i> Pneumonia Among Homosexual Men," <i>Morbidity Mortality Weekly Rept.</i> , Vol. 30(25), Centers for Disease Control, July 3, 1981, pp. 305-308.
*	RA†	Barre-Sinoussi et al., "Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)," <i>Science</i> , 220, 868-871 (1983).

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER L. E. Crane 	DATE <b>05/01/03</b>	page 2 of 5 ¥: Reference not presently available.
<p align="center">*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)</p>		

Form PTO-892 U.S. Department of Commerce	Serial Number <b>09/756,411</b>	Group Art Unit <b>1623</b>	Attachment to Paper Number <b>15</b>
Notice of References Cited	APPLICANT(S) <b>Lori et al.</b>		

**Other References (Including Author, Title, Date, Pertinent Pages, etc.)**

*	SA	Fauci (I), "The Human Immunodeficiency Virus: Infectivity and Mechanisms of Pathogenesis," <i>Science</i> , 239, 617-622 (February 1988).
*	TA	Fauci (II), "Multifactoral Nature of Human Immunodeficiency Virus Disease: Implications for Therapy," <i>Science</i> , 262, 1011-1018 (November 12, 1993).
*	UA	Zack et al., "HIV-1 Entry into Quiescent Primary Lymphocytes: Molecular Analysis Reveals a Labile, Latent Viral Structure," <i>Cell</i> , 61, 213-222 (April 20, 1990).
*	VA	Bukrinsky et al., "Quiescent T Lymphocytes as an Inducible Virus Reservoir in HIV-1 Infection," <i>Science</i> , 254, 233-237 (October 18, 1991).
*	WA	Schnittman et al., "The Reservoir for HIV-1 in Human Peripheral Blood Is a T Cell that Maintains Expression of CD4," <i>Science</i> , 245, 305-308 (July, 1989).
*	XA	Fox et al., "Lymphoid Germinal Centers Are Reservoirs of Human Immunodeficiency Virus Type 1 RNA," <i>Journal of Infectious Diseases</i> , 164, 1051-1057 (December, 1991).
*	YA	Hirsch et al., "Therapy for Human Immunodeficiency Virus Infection," <i>New England Journal of Medicine</i> , 328(23), 1686-1695 (June 10, 1993).
*	ZA†	Pauwels et al., "Rapid and Automated Tetrazolium-Based Colorimetric Assay for the Detection of Anti-HIV Compounds," <i>Journal of Virological Methods</i> , 20, 309-321 (1988).

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.


EXAMINER L. E. Crane <i>L. E. Crane</i>	DATE <b>05/01/03</b>	page 3 of 5 ¥: Reference not presently available.
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		

Form PTO-892 U.S. Department of Commerce	Serial Number <b>09/756,411</b>	Group Art Unit <b>1 6 2 3</b>	Attachment to Paper Number <b>1 5</b>
Notice of References Cited	APPLICANT(S) <b>Lori et al.</b>		

**Other References (Including Author, Title, Date, Pertinent Pages, etc.)**

* <b>RB</b>	<b>Yarchoan et al.</b> , "Clinical Pharmacology of 3'-Azido-2', 3'-dideoxythymidine (Zidovudine) and Related Dideoxynucleosides," <i>New England Journal of Medicine</i> , 321(11), 726-738 (September 14, 1989).
* <b>SB†</b>	<b>Chow et al.</b> , "Use of Evolutionary Limitations of HIV-1 Multidrug Resistance to Optimize Therapy," <i>Nature</i> , 361, 650-654 (1993).
* <b>TB</b>	<b>Lori et al.(III)</b> , "Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus-Type 1 Replication," <i>Science</i> , 266, 801-805 (November 4, 1994).
* <b>UB†</b>	<b>Karlsson et al.</b> , "Hydroxyurea Increases the Phosphorylation of 3'-fluorothymidine and 3'-Azidothymidine in CEM Cells," <i>European Journal of Biochemistry</i> , 186, 689-694 (1989).
* <b>VB†</b>	<b>Marquez et al.</b> , "Acid-Stable 2'-Fluoro Purine Dideoxynucleosides as Active Agents Against HIV," <i>Journal of Medicinal Chemistry</i> , 33(3), 978-985 (1990).
* <b>WB†</b>	<b>Snyder et al. (II)</b> , "The Accumulation of DNA Breaks Due to Incision; Comparative Studies with Various Inhibitors," Ch. 2 in <u>DNA Repair et al. r and Its Inhibition</u> , <u>Nucleic Acids Symposium Series No. 13</u> , Collins et al. eds., IRL Press, Oxford, England, 1984, pp. 13-33.
* <b>XB</b>	<b>Vila et al.</b> , "Absence of Viral Rebound After Treatment of HIV-Infected Patients with Didanosine [ddI] and Hydroxycarbamide [aka Hydroxyurea]," <i>Lancet</i> , 350(9078), 635-636 (August 30, 1997).
* <b>YB</b>	<b>Schoofs</b> , "The Berlin Patient," <u>The New York Times Magazine</u> , pp. 32-35, June 21, 1998.

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER L. E. Crane 	DATE <b>05/01/03</b>	page 4 of 5 ¥: Reference not presently available.
<p align="center">*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)</p>		


Form PTO-892 U.S. Department of Commerce	Serial Number <b>09/756,411</b>	Group Art Unit <b>1 6 2 3</b>	Attachment to Paper Number	<b>1 5</b>
Notice of References Cited	APPLICANT(S) <b>Lori et al.</b>			

**Other References (Including Author, Title, Date, Pertinent Pages, etc.)**

*	ZB†	<b>Balzarini, J.</b> , "Effect of Antimetabolite Drugs of Nucleotide Metabolism on the Anti-Human Immunodeficiency Virus Activity of Nucleoside Reverse Transcriptase Inhibitors," <i>Pharmacology and Therapeutics</i> , 87(2-3), 175-187 (2000).††
*	RC†	<b>Gao et al. (II)</b> , "Enhancement by Hydroxyurea of the Anti-Human Immunodeficiency Virus Type 1 Potency of 2'- $\beta$ -Fluoro-2',3'-dideoxyadenosine in Peripheral Blood Mononuclear Cells," <i>Biochemical Pharmacology</i> , 50(2), 274-276 (1995).††
	SC†	<b>Masood et al.</b> , "2'-Fluoro-2',3'-dideoxyarabinosyladenine: A Metabolically Stable Analogue of the Antiretroviral Agent 2',3'-Dideoxyadenosine," <i>Molecular Pharmacology</i> , 37, 590-596 (1990).
¥	TC	<b>Hitchcock et al.</b> , "Biochemical Pharmacology of 2'-Fluoro-2',3'-dideoxyarabinosyladenine, an Inhibitor of HIV with Improved Metabolic and Chemical Stability over 2',3'-Dideoxyadenosine," <i>Antiviral Chem. Chemother.</i> , 1, 319-327 (1990).
	UC	<b>Gao et al. (III)</b> , "Differential Phosphorylation of Azidothymidine, Dideoxycytidine, and Dideoxyinosine in Resting and Activated Peripheral Blood Mononuclear Cells," <i>Journal of Clinical Investigations</i> , 91(5), 2326-2333 (May, 1993).

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

†† Copy kindly supplied by Applicant.

EXAMINER L. E. Crane 	DATE <b>05/01/03</b>	page 5 of 5 ¥: Reference not presently available.
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		

Form PTO-892 U.S. Department of Commerce	Serial Number <b>09/756,411</b>	Group Art Unit <b>1 6 2 3</b>	Attachment to Paper Number <b>1 5</b>
Notice of References Cited	APPLICANT(S) <b>Lori et al.</b>		

### U. S. Patent Documents

*		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	Filing Date If Appropriate
*	A	4,708,818 A	11/24/87	Montagnier et al.	435	005.000	
*	B	5,026,687 A	06/25/91	Yarchoan et al.	514	045.000	
*	C	5,110,600 A	05/05/92	Green	424	450.000	
*	D	5,300,059 A	04/05/94	Rubinstein et al.	604	408.000	
*	E	5,521,161 A	05/28/96	Malley et al. (I)	514	045.000	
*	F	5,736,526 A	04/07/98	Malley et al. (II)	514	045.000	
*	G	5,736,527 A	04/07/98	Malley et al. (III)	514	045.000	
*	H	6,046,175 A	04/04/20	Lori et al. (I)	514	045.000	
*	I	6,093,702 A	07/25/00	Malley et al. (IV)	514	045.000	
*	J	6,194,390 B1	02/27/01	Lori et al. (II)	514	045.000	
*	K	6,093,702 A	07/25/00	Malley et al. (V)	514	045.000	

### Foreign Patent Documents

*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUB-CLASS		
*	L	EP 0,206,497 A2	12/30/86	Europe(EPO)	Wellcome Fndtn	----	----		
*	M	WO87/01284 A1	03/12/87	World(WO/PCT)	US Dept. Commerce	----	----		

### Other References (Including Author, Title, Date, Pertinent Pages, etc.)

*	R	Gao et al.(I), "Low Levels of Deoxynucleotides in Peripheral Blood Lymphocytes: A Strategy to Inhibit Human Immunodeficiency Virus Type 1 Replication," <i>Proc. National Academy Sciences USA</i> , 90, 8925-8928 (October 1993).
---	---	---

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER L. E. Crane <i>[Signature]</i>	DATE <b>05/01/03</b>	page 1 of 5 ¥: Reference not presently available.
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		

09/756,411 - PTO-892

Copy for *[Signature]* FILE [ ] APPLICANT

Part of P. N. **15**